Figure 1
Figure 1. Multimodality targeting of MM in the context of the BM microenvironment. In the center is the MMC (in light pink), with nuclear clumped chromatin and endoplasmic reticulum (ER). The surrounding 5 sections each represent a different modality of anti-MM therapy, with investigational agents outlined in red. In section A is the UPS, closely interacting with the aggresome pathway. Deubiquitinating enzymes USP7 and USP14/UCHL5 are symbolized by a scissors and the 19S ubiquitin (Ub) receptor RPN13 as a receptor associated with the proteasome cap. Section B contains the monoclonal antibodies mAbs) daratumumab (DARA) and SAR650984 (SAR), targeting CD38, as well as elotuzumab (ELO), targeting SLAMF-7, which mediate CDC, direct cytotoxicity from cross-linking, and ADCC. The antibody-drug conjugates (ADCs) indatuximab ravtansine (BT062) and J6M0-mcMMAF (J6M0) target CD138 and BCMA, respectively. Both toxins cause mitotic arrest and apoptosis after being released intracellularly upon internalization of the ADC–target complex and lysosomal lysis. Section C represents several strategies for modulation of cytotoxic immunity. In red is an anti-BCMA CAR-T cell; in orange is an MM-specific cytotoxic T cell activated via direct interaction with MM-DC vaccine or with autologous DC presenting peptides from the PVX-140 vaccine. Two different strategies to modulate epigenetic control of oncosuppressor and oncogene expression are outlined in section D. Nucleosomes are represented as spheres (histones) wrapped in a black thread (DNA). Open nucleosomes with acetylated (Ac) sites are green, whereas closed chromatin structure is pink. The BET bromodomain 4 protein (BRD4) is represented as a red trapezoid, binding to acetylated nucleosomes and inducing Myc transcription. Section E contains a representation of immune checkpoint blockade, with cytotoxic T and NK-T cells represented in green and blue, respectively. PD-1 and its ligand PD-L1 are represented as complementary transmembrane structures on effector cells and target cells (MMCs, myeloid-derived suppressor cells [MDSCs], and pDCs), respectively. Cytotoxic T-lymphocyte-associated protein 4 (CTLA4) and killer cell immunoglobulin-like receptor (KIR) are also pictured on effector cells. Outside the sections, TH-302 hypoxia–activated alkylating agent and NOX-A12 CXCL12 inhibitor are represented. In the 4 corners are key cellular and noncellular elements of the BM niche that contribute to MM pathogenesis: excess of osteoclasts (OC) compared to osteoblasts (OB; upper left corner); increased neoangiogenesis (upper right corner); tumor-tolerant immune system (lower right corner); and cancer-associated fibroblasts (CAF) responsible for the secretion of a pro-MM extracellular matrix (ECM), and MM-associated BM stromal cells (BMSC; lower left corner). Relevant cytokines in the BM milieu are represented as orange ovals. FcR, Fc receptor; HATs, histone acetylases; HGF, hepatocyte growth factor; MIP-1α, macrophage inflammatory protein 1α; PD-L1, programmed cell death ligand 1; RANKL, receptor activator of NF-κB ligand; RBC, red blood cell; TCR, T-cell receptor; TGFβ, transforming growth factor β; TH17, T helper 17 cells; TNFα, tumor necrosis factor α; Treg, regulatory T cell; VEGFA, vascular endothelial growth factor A.

Multimodality targeting of MM in the context of the BM microenvironment. In the center is the MMC (in light pink), with nuclear clumped chromatin and endoplasmic reticulum (ER). The surrounding 5 sections each represent a different modality of anti-MM therapy, with investigational agents outlined in red. In section A is the UPS, closely interacting with the aggresome pathway. Deubiquitinating enzymes USP7 and USP14/UCHL5 are symbolized by a scissors and the 19S ubiquitin (Ub) receptor RPN13 as a receptor associated with the proteasome cap. Section B contains the monoclonal antibodies mAbs) daratumumab (DARA) and SAR650984 (SAR), targeting CD38, as well as elotuzumab (ELO), targeting SLAMF-7, which mediate CDC, direct cytotoxicity from cross-linking, and ADCC. The antibody-drug conjugates (ADCs) indatuximab ravtansine (BT062) and J6M0-mcMMAF (J6M0) target CD138 and BCMA, respectively. Both toxins cause mitotic arrest and apoptosis after being released intracellularly upon internalization of the ADC–target complex and lysosomal lysis. Section C represents several strategies for modulation of cytotoxic immunity. In red is an anti-BCMA CAR-T cell; in orange is an MM-specific cytotoxic T cell activated via direct interaction with MM-DC vaccine or with autologous DC presenting peptides from the PVX-140 vaccine. Two different strategies to modulate epigenetic control of oncosuppressor and oncogene expression are outlined in section D. Nucleosomes are represented as spheres (histones) wrapped in a black thread (DNA). Open nucleosomes with acetylated (Ac) sites are green, whereas closed chromatin structure is pink. The BET bromodomain 4 protein (BRD4) is represented as a red trapezoid, binding to acetylated nucleosomes and inducing Myc transcription. Section E contains a representation of immune checkpoint blockade, with cytotoxic T and NK-T cells represented in green and blue, respectively. PD-1 and its ligand PD-L1 are represented as complementary transmembrane structures on effector cells and target cells (MMCs, myeloid-derived suppressor cells [MDSCs], and pDCs), respectively. Cytotoxic T-lymphocyte-associated protein 4 (CTLA4) and killer cell immunoglobulin-like receptor (KIR) are also pictured on effector cells. Outside the sections, TH-302 hypoxia–activated alkylating agent and NOX-A12 CXCL12 inhibitor are represented. In the 4 corners are key cellular and noncellular elements of the BM niche that contribute to MM pathogenesis: excess of osteoclasts (OC) compared to osteoblasts (OB; upper left corner); increased neoangiogenesis (upper right corner); tumor-tolerant immune system (lower right corner); and cancer-associated fibroblasts (CAF) responsible for the secretion of a pro-MM extracellular matrix (ECM), and MM-associated BM stromal cells (BMSC; lower left corner). Relevant cytokines in the BM milieu are represented as orange ovals. FcR, Fc receptor; HATs, histone acetylases; HGF, hepatocyte growth factor; MIP-1α, macrophage inflammatory protein 1α; PD-L1, programmed cell death ligand 1; RANKL, receptor activator of NF-κB ligand; RBC, red blood cell; TCR, T-cell receptor; TGFβ, transforming growth factor β; TH17, T helper 17 cells; TNFα, tumor necrosis factor α; Treg, regulatory T cell; VEGFA, vascular endothelial growth factor A.

Close Modal

or Create an Account

Close Modal
Close Modal